Shanghai Fosun Pharmaceutical Industry Development Limited Company, Fosun Pharmaceutical wholly owned subsidiary, invested to build Hunan Hansen pharmaceutical LTD (Now renamed as Hunan Hansen Pharmaceutical Co., LTD, hereinafter referred to as Hansen Pharmaceutical), On May 25, it went to public in small and medium-sized enterprises board of Shenzhen Stock Exchange.

Hansen Pharmaceutical (002412) mainly specializes in R&D, manufacturing and selling the Chinese medicine preparation for gastrointestinal diseases, orthopedics disease and cardiovascular and cerebrovascular diseases. The company’s core products are simotang oral liquid, yushangling capsule, suoquan capsules and ginkgo leaf capsule and so on. Hansen pharmaceutical is the high-tech enterprise and key pharmaceutical in Hunan province, incorporating scientific research, production and sales into an organic whole.
It is reported, before initial public offerings of Hansen pharmaceutical, Shanghai Fosun Pharmaceutical Industry Development Limited Company (hereinafter referred to as Pharmaceutical Industry), Fosun Pharmaceutical wholly owned subsidiary, hold 20% Hansen pharmaceutical share; after initial public offerings of Hansen pharmaceutical, the share of Hansen pharmaceutical hold by Pharmaceutical reduced to 14.86%.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (600196. SH) specializes in modern biological medical & health industry, over 10 years’ development, it implemented core competiveness strategy in the respect of R&D, innovation, marketing, merging & integration and team building, and has become a large professional pharmaceutical group regarding pharmaceutical manufacturing as the core and taking the lead of the scale and market role in pharmaceutical commerce, medical diagnostic, medical service and medical instruments.